Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Blood (2025) 146 (Supplement 1): 7546.

https://doi.org/10.1182/blood-2025-7546

Published: 2025

Journal Articles

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Menghan Liu, Wen Gao, Wenrong Huang, Xinan Cen, Yuan Jian, Huixing Zhou, jing jia, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2025-5766

Published: 2025

Journal Articles

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

Gang An, Wenming Chen, Wen Gao, Ting Yang, Lijie Xing, Kaihong Xu, Yan Zhang, Tong Xu, Min Wei, Feng Li, Guojin Wu, Jinying Ning, Lugui Qiu

Blood (2025) 146 (Supplement 1): 2274.

https://doi.org/10.1182/blood-2025-2274

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

Qiling Bu, Yiwen Jiang, Jingjing Deng, Ping Wang, Zhiyao Zhang, Guangzhong Yang, Ying Tian, Wen Gao, Aijun Liu, Leng Yun, Yin Wu, Wenming Chen, Honghu Zhu

Blood (2025) 146 (Supplement 1): 7564.

https://doi.org/10.1182/blood-2025-7564

Published: 2025

Journal Articles

Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma

Yueyi An, Huixing Zhou, Xiaoyun Jin, Shengdian Wang, Wen Gao

Blood (2025) 146 (Supplement 1): 3933.

https://doi.org/10.1182/blood-2025-3933

Published: 2025

Journal Articles

Single-cell transcriptomic analysis reveals impaired immune profiles in elderly AML patients

Yebo Peng, Haixiao Zhang, Yingying Huo, Wen Gao, Ting Shi, Jianpeng Sheng, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 1409.

https://doi.org/10.1182/blood-2025-1409

Published: 2025

Journal Articles

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Yingying Huo, Haixiao Zhang, Yebo Peng, Ting Shi, Ya-Lan Zhou, Chuanying Geng, Wenjing Li, Wen Gao, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 769.

https://doi.org/10.1182/blood-2025-769

Published: 2025

Journal Articles

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Wenjing Li, Yin WU, Chuanying Geng, Aijun Liu, Lefu Huang, Leng Yun, Yanru Zhang, Ying Tian, jing jia, Menghan Liu, Huijuan Wang, Guangzhong Yang, Hong-Hu Zhu, Wenming Chen, Wen Gao

Blood (2025) 146 (Supplement 1): 7590.

https://doi.org/10.1182/blood-2025-7590

Published: 2025

Journal Articles

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

Qingyu Xu, Ya-Lan Zhou, Ting Shi, Chuanying Geng, Wen Gao, Yun Leng, Yin Wu, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5646.

https://doi.org/10.1182/blood-2025-5646

Published: 2025

Journal Articles

The clinical utility of MALDI-TOF MS in multiple myeloma

Jialu Wu, Xia Ge, Zhiyao Zhang, Yufang Liang, Wen Gao, Wenming Chen

Blood (2025) 146 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2025-2230

Published: 2025

Journal Articles

Circulating cell-free BRAFV600E as a biomarker in patients with erdheim-chester disease

Long Chang, Wei-tong Liu, He Lin, Wen Gao, Dao-Bin Zhou, Minghui Duan, Xin-Xin Cao

Blood (2025) 146 (Supplement 1): 2038.

https://doi.org/10.1182/blood-2025-2038

Published: 2025

Journal Articles

Detection of mutation in cell-free DNA predicts poor outcomes in adult patients with langerhans cell histiocytosis

Long Chang, He Lin, Wei-tong Liu, Zheng-Zheng Liu, Wen Gao, Dao-Bin Zhou, Minghui Duan, Xin-Xin Cao

Blood (2025) 146 (Supplement 1): 2035.

https://doi.org/10.1182/blood-2025-2035

Published: 2025

Journal Articles

High-throughput screening uncloaks actionable compounds for ttmv::rara AML

Zhanrui Cheng, Shu Sun, Jiayu Wang, Bei Yang, Gejia Cao, Wen Gao, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 6109.

https://doi.org/10.1182/blood-2025-6109

Published: 2025

Journal Articles

A novel kinase-related gene signature predicts the survival and therapeutic responses of Acute Myeloid Leukemia

Haibo Yu, Yingying Huo, Haixiao Zhang, Wen Gao, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 7011.

https://doi.org/10.1182/blood-2025-7011

Published: 2025

Journal Articles

Immunoglobulin Light Chain Renal Amyloidosis Patients with t(11;14) Have Much More Possibility to be Present As Nephrotic Syndrome

Menghan Liu, Chuanying Geng, Wen Gao, Wenming Chen, Guangzhong Yang

Blood (2024) 144 (Supplement 1): 6876.

https://doi.org/10.1182/blood-2024-202383

Published: 2024

Journal Articles

Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype

Blood (2024) 144 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2024-202323

Published: 2024

Journal Articles

High Resolution Chest Computed Tomography Responses for a Cohort of Erdheim-Chester Disease Patients with Pulmonary Involvement

Long Chang, Luo Wang, Min Lang, Dao-Bin Zhou, Wen Gao, Minghui Duan, Xin-xin Cao

Blood (2024) 144 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2024-198148

Published: 2024

Journal Articles

MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study

Gang An, Lijie Xing, Wenming Chen, Yan Zhang, Wen Gao, Lu-Gui Qiu, Guojin Wu, Jinying Ning, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2024-199423

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma

Single-cell transcriptomic analysis reveals impaired immune profiles in elderly AML patients

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

The clinical utility of MALDI-TOF MS in multiple myeloma

Circulating cell-free BRAFV600E as a biomarker in patients with erdheim-chester disease

Detection of mutation in cell-free DNA predicts poor outcomes in adult patients with langerhans cell histiocytosis

High-throughput screening uncloaks actionable compounds for ttmv::rara AML

A novel kinase-related gene signature predicts the survival and therapeutic responses of Acute Myeloid Leukemia

Immunoglobulin Light Chain Renal Amyloidosis Patients with t(11;14) Have Much More Possibility to be Present As Nephrotic Syndrome

Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype

High Resolution Chest Computed Tomography Responses for a Cohort of Erdheim-Chester Disease Patients with Pulmonary Involvement

MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only